Key points are not available for this paper at this time.
Population
Troponin-negative acute coronary syndrome patients undergoing percutaneous coronary intervention
Comparison
Crushed ticagrelor vs eptifibatide bolus plus clopidogrel
Design
Randomized clinical trial
Answers are grounded in this paper and cite their sources.
Supports eptifibatide-clopidogrel in troponin-negative ACS PCI; hypothesis-generating and requires randomized confirmation before practice change.
=0.035). Post-percutaneous coronary intervention hemoglobin levels were not different between groups. Conclusions Eptifibatide bolus plus clopidogrel led to faster and more potent platelet inhibition than CTIC and reduced periprocedural myocardial infarction and injury in troponin-negative acute coronary syndrome patients undergoing percutaneous coronary intervention, with no significant hemoglobin drop after percutaneous coronary intervention. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02925923.
No takes yet. Share an insight, caveat, or question.
Marian et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: